AndreaBozzo/ceres-open-data-index huggingface dataset:
Patent AT-E400554-T1: [Translated] 2-ARYLETHYL-(PIPERIDINE-4-YLMETHYL)AMINE DERIVATIVES AS MUSCARIINE RECEPTOR ANTAGONISTS

Chemical patent from PubChem database. Patent Number: AT-E400554-T1. Title: Method for Synthesizing Organic Compounds. Filing Date: 1992-11-14. Inventors: Yamamoto, Hiroshi, Schmidt, Hans. Abstract: A method for synthesizing organic compounds is disclosed, comprising reacting starting materials under specific conditions to yield the desired produc... IPC Classifications: A61K, A61P, C07D. This patent covers 29 claims related to 4 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Compound 529376: Val, N-isoBOC TBDMS

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 3-methyl-2-(2-methylpropoxycarbonylamino)butanoate. Molecular Formula: C16H33NO4Si. Molecular Weight: 331.52. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525825: N,N-Dimethyl-N'-(3-ethoxyphenyl)-propionamidine

Chemical compound data from PubChem database. IUPAC Name: N'-(3-ethoxyphenyl)-N,N-dimethylpropanimidamide. Molecular Formula: C13H20N2O. Molecular Weight: 220.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Diuretics: again the first step in the treatment of most patients with hypertension

The results and interpretations of the most recent controlled clinical trials on antihypertensive drugs have fuelled the debate about the drug that should be used to begin treatment for hypertension. Every comparison of diuretics with other drugs has shown that the benefits of diuretics are equivalent to, or better than, other options. These findings, together with other practical reasons, such as left ventricular mass reducing effect, easy administration, few side effects and low cost, suggest that diuretics should regain their primacy as the first step in drug management of hypertension.
Serine / threonine protein phosphatase 5 (PP5) participates in the regulation of glucocorticoid receptor nucleocytoplasmic shuttling

Background
          In most cells glucocorticoid receptors (GR) reside predominately in the cytoplasm. Upon hormone binding, the GR translocates into the nucleus, where the hormone-activated GR-complex regulates the transcription of GR-responsive genes. Serine/threonine protein phosphatase type 5 (PP5) associates with the GR-heat-shock protein-90 complex, and the suppression of PP5 expression with ISIS 15534 stimulates the activity of GR-responsive reporter plasmids, without affecting the binding of hormone to the GR.
        
        
          Results
          To further characterize the mechanism by which PP5 affects GR-induced gene expression, we employed immunofluorescence microscopy to track the movement of a GR-green fluorescent fusion protein (GR-GFP) that retained hormone binding, nuclear translocation activity and specific DNA binding activity, but is incapable of transactivation. In the absence of glucocorticoids, GR-GFP localized mainly in the cytoplasm. Treatment with dexamethasone results in the efficient translocation of GR-GFPs into the nucleus. The nuclear accumulation of GR-GFP, without the addition of glucocorticoids, was also observed when the expression of PP5 was suppressed by treatment with ISIS 15534. In contrast, ISIS 15534 treatment had no apparent effect on calcium induced nuclear translocation of NFAT-GFP.
        
        
          Conclusion
          These studies suggest that PP5 participates in the regulation of glucocorticoid receptor nucleocytoplasmic shuttling, and that the GR-induced transcriptional activity observed when the expression of PP5 is suppressed by treatment with ISIS 15534 results from the nuclear accumulation of GR in a form that is capable of binding DNA yet still requires agonist to elicit maximal transcriptional activation.
Compound 526811: 15-Hydroxy-heptadecanoic acid, methyl ester, tBDMS ether

Chemical compound data from PubChem database. IUPAC Name: methyl 15-[tert-butyl(dimethyl)silyl]oxyheptadecanoate. Molecular Formula: C24H50O3Si. Molecular Weight: 414.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399517-T1: [Translated] VALVE WITH A CIRCULATION CHANNEL, WITH A PROFILED MOUNTING BALLOON AND WITH A DEVICE FOR BLOCKING OFF A FLOW

A urethral valve system includes a fixation balloon that is positioned in and contoured to the geometry of the bladder near the opening to the urethra. The fixation balloon, which is narrower at an end that is closest to the urethra and wider at an opposite end, includes a channel through which urine is directed to flow from the bladder to the urethra. A valve balloon is positioned in the channel and inflates to prevent urine flow through the channel and deflates to allow urine to flow around the balloon and out the end of the channel. The fixation balloon may be attached to a Foley-type catheter, with the catheter providing the channel through the balloon. The fixation balloon then acts as a shock absorber for the system by moving relative to the catheter in response to, for example, a contraction in the bladder. The catheter may contain lumens that provide access to the valve balloon and/or the fixation balloon. The fixation balloon is inserted in a deflated state and inflated to hold the system in place. The fixation balloon remains inflated with the valve balloon providing continence when it is in an inflated state and allowing voiding when it is in a deflated state. Only when the device is to be removed from the body is the fixation balloon deflated.
Compound 525775: 2,4-Dimethyl-5-butyloxazole

Chemical compound data from PubChem database. IUPAC Name: 5-butyl-2,4-dimethyl-1,3-oxazole. Molecular Formula: C9H15NO. Molecular Weight: 153.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525693: p-Methoxybenzylidene-(3-bromophenyl)-amine

Chemical compound data from PubChem database. IUPAC Name: N-(3-bromophenyl)-1-(4-methoxyphenyl)methanimine. Molecular Formula: C14H12BrNO. Molecular Weight: 290.15. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Table 11. 2011-2012 NSDUH Perceptions of Great Risk of Having Five or More Drinks of an Alcoholic Beverage Once or Twice a Week, by Age Group and State

Table 11. Perceptions of Great Risk of Having Five or More Drinks of an Alcoholic Beverage Once or Twice a Week, by Age Group and State. Results are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Cellophane based mini-prep method for DNA extraction from the filamentous fungus

Background
          Methods for the extraction of DNA from filamentous fungi are frequently laborious and time consuming because most of the available protocols include maceration in liquid nitrogen after the mycelium has been grown in a liquid culture. This paper describes a new method to replace those steps, which involves the growth of the mycelium on cellophane disks overlaid on solid medium and the use of glass beads for cell wall disruption.
        
        
          Results
          Extractions carried out by this method provided approximately 2 μg of total DNA per cellophane disk for the filamentous fungus Trichoderma reesei. To assess the DNA's quality, we made a PCR (Polymerase Chain Reaction) amplification of a gene introduced by a transformation in this fungus's genome (hph gene), with successful results. We also confirmed the quality of the DNA by the use of Southern blotting to analyze the presence of the same gene, which was easily detected, resulting in a sharply defined and strong band.
        
        
          Conclusions
          The use of this method enabled us to obtain pure DNA from Trichoderma reesei, dispensing with the laborious and time-consuming steps involved in most protocols. The DNA obtained was found to be suitable for PCR and Southern blot analyses. Another advantage of this method is the fact that several samples can be processed simultaneously, growing the fungus on multiple well cell culture plates. In addition, the absence of maceration also reduces sample handling, minimizing the risks of contamination, a particularly important factor in work involving PCR.
Patent AT-E401273-T1: [Translated] GRIPPER DEVICE

The device (1) comprises multiple grippers (5) arranged together in a position with a pre-determined distance. A rocker comprises a swiveling point at the frame (4), where a drive unit (7) has a translational movement (10) for moving two adjacent grippers over different lengths. The coupling elements are connected with the rocker of other gripper by one swiveling point.
Compound 525075: Naphthalene, 2-(1-methylpropyl)

Chemical compound data from PubChem database. IUPAC Name: 2-butan-2-ylnaphthalene. Molecular Formula: C14H16. Molecular Weight: 184.28. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E39991-T1: [Translated] SAFETY LOCKING DEVICE ON GUARDS TO PREVENT INTERVENTION IN HAZARDOUS SPACES.

1. Device for safety interlocking in protection equipment for preventing reaching into spaces which are dangerous, particularly in the came of machines with dangerous movements or with current-carrying equipment in housings, whereby a toggle lever (14, 15) is provided with a pivoted locking lever (8), which is provided with two dead centre positions and which interacts with an actuating part (9) being mounted stationary on the protection device (5) and being provided with a locking cam, in such a way that in the one dead centre position of the toggle lever (14, 15) the locking lever (8) and the actuating part (9) interlock with each other and the dangerous operating condition may be switched on, and that in the other dead centre position the dangerous operating condition is switched off and the actuating part (9) with the protection device (5) is released, characterised in that a pull lever (19) is linked to the centre joint (14a) of the toggle lever (14, 15), said pull lever being connected to the anchor (18a) of a holding magnet (18) by means of a joint (18b).
Compound 526028: 17A-11-Dehydroestradiol, TMS

Chemical compound data from PubChem database. IUPAC Name: trimethyl-[(13-methyl-3-trimethylsilyloxy-6,7,8,9,14,15,16,17-octahydrocyclopenta[a]phenanthren-17-yl)oxy]silane. Molecular Formula: C24H38O2Si2. Molecular Weight: 414.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528380: 2,3-Dichloro-4-hydroxybenzaldehyde

Chemical compound data from PubChem database. IUPAC Name: 2,3-dichloro-4-hydroxybenzaldehyde. Molecular Formula: C7H4Cl2O2. Molecular Weight: 191.01. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400507-T1: [Translated] DEVICE FOR STORING AND TRANSPORTING GOODS AND INSERTS THEREOF

At least one insert ( 6 ) for insertion into a bag ( 3 ) for receiving a discrete article, said insert ( 6 ) being preferably located in a portion of the bag taking up substantially the main load of the discrete article and being moveable relative to the bag, securable to the bag and removable from the bag. The invention also includes a device for storing and transporting discrete articles, having at least one bag ( 3 ) in which the discrete article can be received, wherein it comprises at least one insert ( 6 ), as described above, in the region of the bag ( 3 ) taking up substantially the main load of the discrete article, said insert being movable relative to the bag and detachably secured to the bag ( 3 ).
Compound 528174: 1,3-Cyclopentadiene, 2-butyl

Chemical compound data from PubChem database. IUPAC Name: 2-butylcyclopenta-1,3-diene. Molecular Formula: C9H14. Molecular Weight: 122.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401792-T1: [Translated] BAKERY YEASTS WITH IMPROVED TOLERANCE TO HIGH SUGAR CONTENT IN DOUGH AND TO WEAK ORGANIC ACIDS

Breadmaking yeast which is a variety of Saccharomyces cerevisiaeas submitted to the CNCM (Collection Nationale de Cultures de Micro-organisms, Institut Pasteur) on 12 February and 25 November 2003 under the following numbers: I-2971, I-3142, I-3143, or other varieties of the same family, is new. Breadmaking yeast which is a variety of Saccharomyces cerevisiaeas submitted to the CNCM (Collection Nationale de Cultures de Micro-organisms, Institut Pasteur) on 12 February and 25 November 2003 under the following numbers: I-2971, I-3142, I-3143, or other varieties of the same family, is new. The yeast is used for making a dough in which fermentation is carried out in the presence of osmotic pressure similar to that occurring in doughs with a sugar content of at least 15 per cent relative to the amount of flour, and preferably 40 per cent, and containing mould inhibitors. The mould inhibitors are preferably in the form of weal organic acids or their salts, and especially calcium propionate.
Do multiple outcome measures require p-value adjustment?

Background
          Readers may question the interpretation of findings in clinical trials when multiple outcome measures are used without adjustment of the p-value. This question arises because of the increased risk of Type I errors (findings of false "significance") when multiple simultaneous hypotheses are tested at set p-values. The primary aim of this study was to estimate the need to make appropriate p-value adjustments in clinical trials to compensate for a possible increased risk in committing Type I errors when multiple outcome measures are used.
        
        
          Discussion
          The classicists believe that the chance of finding at least one test statistically significant due to chance and incorrectly declaring a difference increases as the number of comparisons increases. The rationalists have the following objections to that theory: 1) P-value adjustments are calculated based on how many tests are to be considered, and that number has been defined arbitrarily and variably; 2) P-value adjustments reduce the chance of making type I errors, but they increase the chance of making type II errors or needing to increase the sample size.
        
        
          Summary
          Readers should balance a study's statistical significance with the magnitude of effect, the quality of the study and with findings from other studies. Researchers facing multiple outcome measures might want to either select a primary outcome measure or use a global assessment measure, rather than adjusting the p-value.
Compound 526186: 2-(2-Furyl)thiazole

Chemical compound data from PubChem database. IUPAC Name: 2-(furan-2-yl)-1,3-thiazole. Molecular Formula: C7H5NOS. Molecular Weight: 151.19. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399930-T1: [Translated] THERMAL STORAGE SYSTEM FOR A LARGE AMOUNT OF ENERGY AND ITS SHORT-TERM USE ON A SHIP

The large quantity energy storage system short period freeing energy has a principal cylinder (3) containing a large quantity of liquid such as water. A heat exchanger (4) in the cylinder is fed with hot exhaust gas from a thermodynamic machine such as a gas turbine. The water is stored at high pressure between 220-400 bar and at a temperature of about 600 degrees C. The stored water can be used to quickly power a hydrojet.
Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features

Background
          The growth and metastasis of tumors depend on the development of an adequate blood supply via angiogenesis. Recent studies indicate that the inducible nitric oxide synthase (iNOS), vascular endothelial growth factor (VEGF) and the tumor suppressor p53 are fundamental play-markers of the angiogenic process. Overexpression of iNOS and VEGF has been shown to induce angiogenesis in tumors. P53 suppresses angiogenesis by down-regulating VEGF and iNOS. The correlation of expression of p53, VEGF and iNOS and clinical features in gastric carcinogenesis, however, has not been well characterized.
        
        
          Methods
          The expression of p53, iNOS and VEGF in gastric precancerous and cancerous lesions and its relation with the clinical features was determined with immunohistochemistry (avidin-biotin-peroxidase complex method) on 55 randomly selected GC patients and 60 symptom-free subjects from the mass survey in the high-incidence area for GC in Henan, northern China.
        
        
          Results
          The positive immunostainig rates for p53, iNOS and VEGF in gastric carcinomas were 51%, 44% and 51%, respectively, and correlated well with TNM stages, but did not show significant difference among the groups with different degrees of gastric wall invasion depth by GC. A positive immunostaining reaction for the iNOS protein was significantly correlated with lymph node metastasis (p = 0.019; Spearman correlation coefficient). P53 protein accumulation was higher in the poorly-differentiated gastric carcinoma than in well-differentiated one. In gastric biopsies, no positive immunosatining was observed for p53, iNOS and VEGF in the histologically normal tissue and chronic superficial gastritis (CSG). However, p53, iNOS and VEGF positive immunostaining was observed in the tissues with different severities of lesions of chronic atrophic gastritis (CAG), intestinal metaplasia (IM) and dysplasia (DYS), and the positive rates increased with the lesion progression from CAG to IM to DYS. A high coincidental positive and negative immunostaining rate for p53, iNOS and VEGF was observed both in biopsy samples with CAG, IM and DYS from the symptom-free subjects and in gastric cancer tissue from the GC patients.
        
        
          Conclusions
          The present results indicated that p53 protein accumulation and increased expression of iNOS and VEGF might be responsible for gastric carcinogenesis and tumor aggressiveness of gastric cancer.
Compound 528577: tert-Butyl(dimethyl)silyl heptadecanoate

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] heptadecanoate. Molecular Formula: C23H48O2Si. Molecular Weight: 384.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401038-T1: [Translated] AUTOMATIC LUNG PARAMETERS ESTIMATION

A device for determining one or more respiratory parameters relating to an individual is disclosed, as well as a method for determining one or more respiratory parameters by means of the device, wherein the individual is suffering from hypoxemia or is at risk of hypoxemia. However, the method and the device may also be applied to healthy individual e.g. for testing of medicaments. The device is controlled by a computer equipped with suitable software and includes functionality for on-line continuous data collection, automatic assessment of the timing of measurements, automatic assessment of the next target (oxygen saturation of arterial blood (SpO2)), automatic assessment of the appropriate fraction of oxygen in inspired gas (FIO2) settings to achieve the target SpO2, automatic control of the FIO2, on-line parameter estimation, and automatic assessment of the number of measurememts requied.
Covered Recipient Profile Supplement

The Covered Recipient Profile Supplement file contains information about physicians and non-physician practitioners who have been indicated as recipients of payments, other transfers of value, or ownership and investment interest in payment records, as well as physicians and non-physician practitioners who have been identified as principal investigators associated with research payment records published by Open Payments.

This file contains only those physicians that have at least one published payment record in this cycle of the publication as of January 30, 2025. The criteria used by the Centers for Medicare & Medicaid Services (CMS) to determine which payment records are eligible for publication is available in the Open Payments Methodology and Data Dictionary Document. This document can be found on the Resources page of the Open Payments website (https://www.cms.gov/OpenPayments/Resources). The Methodology and Data Dictionary Document also includes information on the data collection and reporting methodology, data fields included in the files, and any notes or special considerations that users should be aware of.
Safety Assessment Family Evaluation—Family Connections (SAFE-FC) Program Manual

This PII grantee program manual provides detailed information about the implementation process of the Washoe County Department of Social Services (WCDSSS) Safety Assessment Family Evaluation—Family Connections (SAFE-FC) program. Its purpose is to assist others in the field in replicating or adapting SAFE-FC for their local use. Readers will find background information, lessons learned, and other practical information based on the experience of the WCDSS team. The manual can be especially helpful if you are considering implementation of the intervention, interested in addressing the needs of similar target populations, or interested in lessons learned from real-world implementation experiences. Together, the PII program manuals help to build a base of replicable interventions that can serve the complex needs of diverse communities of children and families.

Metadata-only record linking to the original dataset. Open original dataset below.
MeSH 2025 Update - Replace Report

<b>(Includes MeSH 2023 and 2024 changes)</b>  The MeSH 2025 Update - Replace Report lists Descriptors and Supplementary Concept Records (SCRs) where an existing MeSH term has been replaced by another term.  Note that replacement terms are not necessarily new to the vocabulary; terms are sometimes consolidated under or moved to other existing terms.  <b>This report includes MeSH changes from previous years, starting from 2023.</b>
Compound 526897: 2-(2-Isopentoxyethoxy)ethyl acetate

Chemical compound data from PubChem database. IUPAC Name: 2-[2-(3-methylbutoxy)ethoxy]ethyl acetate. Molecular Formula: C11H22O4. Molecular Weight: 218.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.